Treatment with dupilumab led to significant improvements in disease remission in patients with bullous pemphigoid, an autoimmune blistering skin disease. The phase 2/3 LIBERTY-BP ADEPT trial ...

This latest FDA decision marks the first approval for SNY's Sarclisa as a first-line treatment for multiple myeloma patients.

Recommendation based on a phase 3 study showing a significantly greater proportion of children on Dupixent achieved histological remission, compared to placebo, consistent with improvements seen in ...

EMA committee recommends approval of Sanofi & Regeneron’s Dupixent to treat eosinophilic esophagitis in children as young as 1 year old: Paris Monday, September 23, 2024, 11:00 ...

Before the FDA approved AstraZeneca’s Fasenra, Nucala was the only therapy for treating eosinophilic granulomatosis with ...

Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old Recommendation based on a phase 3 study showing a significantly ...

Recommendation based on a Phase 3 trial showing a significantly greater proportion of children on Dupixent achieved histological remission ...

AstraZeneca AZN announced that the FDA has approved its marketed asthma drug, Fasenra (benralizumab) for a new indication.

Responding to rising mpox cases in Africa, the World Health Organization declared a public health emergency of international ...

Vascular space involvement, venous or lymphatic, does not affect classification. ‡ The presence of bullous edema is not sufficient to classify a tumor as T4. Table 2. Studies Investigating the ...